ACIU
NASDAQ · Biotechnology
Ac Immune Sa
$2.92
+0.06 (+2.10%)
Financial Highlights (FY 2025)
Revenue
116.52M
Net Income
209.8K
Gross Margin
67.7%
Profit Margin
0.2%
Rev Growth
+18.7%
D/E Ratio
0.72
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 67.7% | 67.7% | 67.7% |
| Operating Margin | 0.2% | 0.2% | 0.2% |
| Profit Margin | 0.2% | 0.2% | 0.2% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 116.52M | 119.79M | 119.57M |
| Gross Profit | 78.94M | 81.15M | 81.00M |
| Operating Income | 198.3K | 217.2K | 194.6K |
| Net Income | 209.8K | 199.8K | 200.3K |
| Gross Margin | 67.7% | 67.7% | 67.7% |
| Operating Margin | 0.2% | 0.2% | 0.2% |
| Profit Margin | 0.2% | 0.2% | 0.2% |
| Rev Growth | +18.7% | -0.9% | +8.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 133.57M | 114.17M | 132.63M |
| Total Equity | 185.53M | 166.00M | 182.25M |
| D/E Ratio | 0.72 | 0.69 | 0.73 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 267.6K | 316.5K | 305.4K |
| Free Cash Flow | 236.0K | 248.3K | 178.6K |